iSpecimen Inc. 于今日正式宣告，其总额达500万美元的普通股与预权证公开发售项目已圆满落幕。此次发行不仅涵盖了普通股，还包括了预筹资金权证，为公司发展注入了可观的资金动力。整个发行过程严格按照既定计划推进，最终顺利实现交割。这一里程碑式的融资事件，标志着iSpecimen在资本市场上的又一重要进展，为其后续业务拓展与战略布局提供了坚实的财务支撑。
iSpecimen Inc. 于今日正式宣告，其总额达500万美元的普通股与预权证公开发售项目已圆满落幕。此次发行不仅涵盖了普通股，还包括了预筹资金权证，为公司发展注入了可观的资金动力。整个发行过程严格按照既定计划推进，最终顺利实现交割。这一里程碑式的融资事件，标志着iSpecimen在资本市场上的又一重要进展，为其后续业务拓展与战略布局提供了坚实的财务支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.